Novo Nordisk partners with Anthropic to speed drug development using Claude Science
Polymarket · x · 2026-09-16
Polymarket gives only a 3% chance of FDA approving Eli Lilly's Retatrutide this year ($586K volume). The triple-agonist peptide drug is in trials for obesity, fatty liver, type-2 diabetes, and more.
In the same thread, Polymarket relayed breaking news: Ozempic maker Novo Nordisk is partnering with Anthropic to accelerate drug development using Claude Science.
More from Companies & People
- Tailscale called a 'single point of failure' for startups as acquisition chatter splits devs — TheZachMueller · 2026-11-02
- Ex-Shopify engineer: the smartest people I knew all left for frontier AI labs — smlpth · 2026-11-02
- Harvard releases 6 free AI lectures covering GenAI, prompt engineering and RAG — Aiden_Tech_Ai · 2026-11-02
- HUMAIN partners with Microsoft to bring HUMAIN ONE into Microsoft 365 — HUMAIN · 2026-11-02
- Grok, Cursor and X account merge creates absurd login loop for users — oran_ge · 2026-11-02
- Gradio teases NeurIPS 2026 ML Intern paper-reproduction hackathon — Gradio · 2026-11-02